Eloxx Pharmaceuticals Inc (ELOX)
Eloxx Pharmaceuticals Inc (ELOX) is a NASDAQ-listed healthcare company whose common stock represents an equity interest in the business. The company is associated with pharmaceutical research focused on therapies for rare genetic conditions, especially those linked to nonsense mutations. Its work has included programs aimed at kidney and skin disorders, along with related early-stage and partnered development efforts. As a listed common equity security on NASDAQ, ELOX reflects participation in the company rather than a separate fund, note, or depositary receipt. Investors reviewing this security are typically looking at the operating company’s research pipeline and development-stage profile.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ELOX
|
$7.90
|
-32.5% Downside
|
Overvalued
|
$43
|
267.5% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 4, 2026
|
-5.9x
|
-6.2x
|
—
|
47.023 M
|
52.685 M
|
20.1%
|
45.1%
|
-52.9
|
—
|
161.5%
|
